aTyr Pharma, Inc.

10240 Sorrento Valley Road, Suite 300

San Diego, CA, 92121

 

 

November 16, 2023

 

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attn: Daniel Crawford

Re: aTyr Pharma, Inc.

Registration Statement on Form S-3 (File No. 333-275455)

Request for Acceleration of Effective Date

Ladies and Gentlemen:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, aTyr Pharma, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) accelerate the effective date of the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) and declare the Registration Statement effective as of 4:00 p.m. Eastern time, on November 20, 2023, or as soon thereafter as possible, or at such other time as the Company or its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. The Company hereby authorizes each of Charles J. Bair and Katherine Denby of Cooley LLP to make such a request on its behalf.

Once the Registration Statement has been declared effective, please orally confirm that event with Katherine Denby of Cooley LLP at (202) 776-2070 or kdenby@cooley.com.

 

Sincerely,
aTyr Pharma, Inc.
By:		/s/ Jill Broadfoot
		Jill Broadfoot
		Chief Financial Officer

 

---